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Abstract
Background Percutaneous transluminal septal myocardial
ablation using microsphere embolisation is a new interven-
tional technique to treat patients with hypertrophic obstruc-
tive cardiomyopathy.
Methods and results In two patients, considered at high risk
for myectomy, targeted septal perforators were occluded
with microsphere embolisation instead of alcohol ablation
to reduce left ventricular outflow gradient. In both cases the
left ventricular outflow tract gradient was immediately re-
duced. No adverse events occurred.
Conclusion This is the first clinical experience with
Embozene®Microspheres in the Netherlands as an alternative
for alcohol septal ablation. In both cases it resulted in imme-
diate improvement in the haemodynamics, without any ad-
verse events.
Keywords Hypertrophic cardiomyopathy . Percutaneous
transluminal septal myocardial ablation . Microsphere
embolisation
Introduction
Dynamic obstruction of the left ventricular outflow tract
(LVOT) is an important component of the pathophysiology
of hypertrophic cardiomyopathy (HCM) and is described in
almost 70% of HCM patients [1]. Therapy in severely
symptomatic patients aims at reducing the extent of the
LVOT obstruction, either medically using negative inotropic
drugs or invasively by either myectomy or percutaneous
transluminal septal myocardial ablation (PTSMA) using
alcohol [2, 3]. PTSMA precludes general anaesthesia,
sternotomy and cardiopulmonary bypass and thus results
in an overall shorter in-hospital stay as compared with
surgical myectomy. Conversely, PTSMA may be associated
with a higher permanent pacemaker implantation rate for
total atrioventricular block [4]. Furthermore, there is ongo-
ing debate on the long-term impact of the resultant myocar-
dial scar with arrhythmogenic potential [5]. In the current
guidelines PTSMA is an alternative intervention for selected
patients who are not optimal surgical candidates [2, 3].
Alcohol has been traditionally used for PTSMA. Its in-
herent cardiotoxicity and the risk of procedural alcohol
spilling into the left anterior descending artery (LAD) have
spurred interest in reliable and potentially safer embolic
alternatives. There is vast experience with microspheres as
an embolic agent to control bleeding or occlude the blood
supply of certain tumours or arteriovenous malformations.
Microspheres allow an easy, safe and targeted delivery [6,
7]. Recently, Embozene® Microspheres were demonstrated
by Latsios et al. [8] as a potential alternative for alcohol in
PTSMA. The aim of this report is to demonstrate the safety
and efficacy of PTSMA using Embozene® Microspheres.
Material and methods
Microspheres
Embozene® Microspheres are specially designed spherical
embolic agents, developed by CeloNova Biosciences Inc.
(San Antonio, TX, USA). The microspheres are hydrogel
cores with an anorganic polymer surface (Polyzene®-F),
which is biocompatible and not absorbable. There are several
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different sizes, which range from 40 μm to 900 μm in diam-
eter, and each size has a different colour. For PTSMA the use
of the 75 μmmicrospheres is recommended. A total of 0.6 ml
of microspheres solution is diluted with 6 ml of contrast agent
for optimal deliverability and visualisation.
Patients
Two HCM patients (age 64 and 77 years) with severe LVOT
obstruction (>90 mmHg at rest) were selected for PTSMA
because of invalidating symptoms (New York Heart Asso-
ciation (NYHA) functional class IV) despite optimal
medical therapy. Based on multiple comorbidities, both
patients were thought to be unsuitable for surgery by
multidisciplinary heart team consensus and thus were
considered for PTSMA. Both patients provided written
informed consent for the procedure.
Intervention
The invasive PTSMA procedure evolves under transtho-
racic echocardiographic monitoring and conscious seda-
tion. The right and left femoral artery and right femoral
vein are cannulated using the standard Seldinger tech-
nique. A temporary pacemaker lead is placed in the
apex of the right ventricle. Full anticoagulation is
obtained with heparin aiming for an activated clotting
time between 250 and 300 s. A 6F double lumen
Langston™ pigtail catheter is advanced into the left
ventricle allowing simultaneous pressure recordings in
the left ventricle and the ascending aorta. The LVOT
gradient is measured invasively and simultaneously with
continuous wave Doppler throughout the procedure. The
Brockenbrough-Braunwald-Morrow sign is assessed at
baseline by artificially provoking ventricular ectopy
(Fig. 1). The left main coronary artery is selectively
engaged with a 6F Judkins left guiding catheter. After
visual assessment of the septal perforator branches of the LAD
the first or second septal perforator is wired with a 0.014”
hydrophilic coronary guidewire introduced into a 1.50×
15 mm over-the-wire (OTW) balloon (Trek™, Abbott Vascu-
lar). The OTW balloon is advanced into the septal perforator
and inflated up to 6 atmospheres. After removal of the coro-
nary guidewire, 2 ml of echo contrast (Sonovue, Bracco Di-
agnostics, Milan, Italy) is selectively injected into the septal
perforator through the inner lumen of the OTW balloon to
allow echocardiographic identification of the basal left ven-
tricular septum as appropriate anatomical target for the micro-
spheres (Fig. 2). Subsequently, with the balloon still inflated,
0.6 ml of Embozene Microspheres are injected. Filling of the
septal perforator with eventual stasis of the injected solution is
confirmed by fluoroscopy and continuous invasive
haemodynamic monitoring demonstrates progressive reduc-
tion in LVOT gradient. The OTW balloon is deflated and
removed. Figure 3 illustrates a favourable reduction in LVOT




Both procedures were carried out uneventfully. No al-
lergic reactions were reported after the use of micro-
spheres. Transient per-procedural atrioventricular
conduction disturbances were noted in one of the pa-
tients. The temporary pacemaker wire could be safely
removed after 24 h. Neither patient required a perma-
nent pacemaker implantation.
Fig. 1 Baseline coronary angiography (a) of the targeted septal artery (black arrow) and left ventricular outflow tract gradient measured with
continuous wave Doppler (b) and invasively (c) direct before the procedure
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Efficacy
Continuous recording of the LVOT gradient revealed an
almost instant reduction of the LVOT pressure gradient
(−50 mmHg and −60 mmHg) in both patients. Focal septal
wall infarction was obtained as demonstrated by peak CK-
MB levels (20 resp. 227 μg/L) and echocardiographic con-
firmation of hypokinesis and thinning of the basal septal
wall.
Discussion
Alcohol injection in the septal artery is the most commonly
used technique for PTSMA in patients with hypertrophic
obstructive cardiomyopathy (HOCM). However, due to the
direct toxicity of the alcohol on the myocardial tissue and
the risk of leakage in the LAD with subsequent anterior wall
infarction, this procedure is not without risks. Coil
embolisation has been proposed as an alternative for alco-
hol. Coils, like microspheres, may provide the opportunity
to create a more controlled infarction. However, drawbacks
of this technique are persistence or reoccurrence of LVOT
obstruction during long-term follow-up and the risk of
periprocedural migration of coils to the LAD with subse-
quent complications such as myocardial infarction and rare-
ly a ventricular septal defect [9, 10].
For the first time in the Netherlands, we used Embozene®
Microspheres as an alternative for alcohol to perform
PTSMA in two patients and confirm its feasibility, corrob-
orating the findings by the Siegburg group, where in one
patient the LVOT obstruction was reduced from 70 to
10 mmHg without any complications [8]. The immediate
improvement in haemodynamics and decrease of LVOT
gradient is most likely caused by the focal infarction and
subsequent akinesia of the septal wall. Long-term results need
further research, but it is expected that due to thinning of the
myocardium the LVOT gradient will further decrease.
Fig. 3 Post-procedural situation with angiography (a) showing that targeted septal artery is no longer visible (black arrow) and decrease in left
ventricular outflow tract gradient measured with continuous wave Doppler (b) and invasively (c) directly after the procedure
Fig. 2 Balloon inflation (a) in targeted septal artery (red arrow) and contrast agent downstream of the balloon (red circle). Opacification of the
targeted septal area on 2D echocardiography (b)
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Microsphere embolisation in these two patients was safe and
effective in inducing focal basal septal wall infarction. Its higher
viscosity makes it safe to inject and reduces the risk of spilling
into the LAD. Also the absence of intrinsic cardiotoxic effects
(as seen with alcohol) may preclude untoward acute myocardial
damage and create a more controlled infarction.
Conclusion
This is the first clinical experience with Embozene® Micro-
spheres in the Netherlands as an alternative for the use of
alcohol in PTSMA in severely symptomatic patients with
HOCM. In both cases it resulted in immediate improvement
in haemodynamics, without any adverse events.
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